An original study revealed that in metastatic CRC patients receiving an anti-VEGF monoclonal antibody bevacizumab and capecitabine plus oxaliplatin therapy, overexpression of miR-664-3p and downregulation of miR-455-5p correlated with improved OS and PFS [91]. Here, VEGFA is linked to colorectal carcinoma.